StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$34.42−1.49 (-4.15%)

Close on Nov 18, 2026Market cap $1.18BP/E –Yield –

Nektar Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Nektar Therapeutics's pe ratio was 8.1× on Jul 31, 2019, against 395.7× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2019Jul 31, 20198.1×−0.2
2018Dec 31, 20188.3×−387.4
2015Oct 30, 2015395.7×–

More Nektar Therapeutics figures

See a number that looks wrong?